Abiopharma

DEXCOM INC (DXCM) Reports the reporting period Financial Results DEXCOM INC (DXCM) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: $1.19
• Net Income: 0.56
• EPS: Not disclosed
• Cash and equivalents: $2.42 billion
  • anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Dexcom’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings filed with the Securities and Exchange Commission. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this communication or to conform these forward-looking statements to actual results.INVESTOR RELATIONS CONTACT:Sean ChristensenSenior Vice President - Finance and Investor Relationsinvestor-relations@dexcom.com(858) 203-6657